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Abstract 
The isolation and structural characterization of three new heterocyclic and macrocyclic peptides, 
balgacyclamides A–C from Microcystis aeruginosa EAWAG 251 is reported. The constitutions 
were determined by 2D-NMR methods and mass spectrometry and the configurations were 
assigned after ozonolysis and hydrolysis by HPLC-MS methods using Marfey's method as well 
as GC-MS using authentic standards. Balgacyclamides A and B were active against Plasmodium 
falciparum K1 in the low micromolar range, while displaying low toxicity to rat myoblasts. 
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Cyclic peptides and derived macrocycles have recently received significant interest in a variety 
of fields, ranging from biosynthesis studies to drug discovery and development,1 The potentially 
large, but structurally often well defined conformational space sampled, combined with the 
variety of amino acids renders peptides ideally suited to interact with many receptors or to 
interfere with protein/protein interactions.1 Cyanobactins constitute a particular subset of cyclic 
peptides produced by cyanobacteria and can be defined as cyclic, ribosomally produced peptides 
(RiPP)2 containing heterocyclic modifications.3 They have been found not only in the producing 
organism, but also in other animals where they have been suggested to be of symbiotic or dietary 
origin.4 A particular subset, the cyclamides are structurally well defined macrocyclic 
hexapeptides, where often hydrophobic residues flanked by heterocyclic rings such as oxazol(ine) 
or thiazol(ine) residues are observed.5-8 While cyclamide biosynthesis has been investigated,2-4,5m 
the bioactivity of these compounds both in their ecological niche as well as in a therapeutic 
setting has received much less attention. Early assumptions on the bioactivity suggested a role as 
allelochemicals,7 which has been supported by algicidal effects.7,8 Another seemingly unrelated 
activity is related to multidrug-resistance reversing activity, which has been reported for several 
members of this family.9 Most interestingly, Gerwick and coworkers reported significant 
antimalarial activity for the venturamides.10 Independently, we have determined antimalarial 
activity for the aerucyclamides11 that displayed improved activity when compared to an earlier 
study.10 The best compound in this series, aerucyclamide B displayed an antimalarial IC50 value 
of 0.7 μM against the Plasmodium falciparum K1 strain with a high selectivity over the L6 rat 
myoblasts cell line. Aerucyclamide B was taken up as a lead structure for a medicinal chemistry 
follow-up program by Serra and coworkers that built on the first successful total synthesis of this 
compound.12 Whereas these authors were able to briefly delineate the first structure activity 
 4 
relationships, the role of the different units on activity remain unclear. The current main 
hypothesis suggests that the degree of unsaturation of the heterocyclic rings is correlated with 
biological activitiy,10–12 with higher unsaturation leading to more potent compounds. While this 
hypothesis is supported by several examples10–12 (e.g. oxidation of an thiazoline to an thiazole in 
aerucyclamide A and B led to 10 times increased activity),11b more compounds are needed to 
corroborate these observations. In this study, we report on the isolation of new cyclamides from 
cyanobacteria, and evaluate their antimalarial properties in the P. falciparum K1 assay. 
The balgacyclamides were isolated from aqueous methanolic extracts of Microcystis 
aeruguinosa EAWAG 251 (identical to PCC 7820). These compounds were purified by a 
combination of C18-SPE, semi-preparative and analytical reversed-phase HPLC methods. The 
structure determination proved to be challenging due to the low isolation yield of 0.55 mg, 0.15 
mg, and 0.80 mg per 15 liters of culture, for the balgacyclamides A (1), B (2) and C (3) 
respectively. 
 
Balgacyclamide A (1) displayed an exact mass of m/z 533.2552, which supports the molecular 
formula C25H37N6O5S for the [M + H]+ pseudomolecular ion. The 1H spectrum (DMSO-d6, 500 
MHz) displayed the typical pattern of a peptide (Table 1). Three NH resonances were present as 
doublets. Based on characteristic signals and COSY correlations, the fragments NH-Ala, NH-Val 
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and NH-Ile were assigned. HSQC and HMBC experiments were used to assign the 13C chemical 
shifts. Furthermore, two Thr residues missing the NH resonance were assigned as 
methyloxazoline (MeOzn) moieties. The last fragment was assigned as a thiazole (Tzl) based on 
its characteristic signals (H-18 Tzl, singlet, ∂H 8.30 ppm, C-18 Tzl ∂C 126.4 ppm).13 The sequence 
of the amino acids was challenging to determine because of the presence of resonance overlap in 
the 1H and 13C spectra. HMBC long-range correlations were measured in two different solvents, 
DMSO-d6 and CDCl3, to establish the sequence (Figure 1; additional NMR data in CDCl3 are 
available in the Supporting Information). From the HMBC spectrum in DMSO-d6, correlations 
from H-2 of MeOzn1 to C-5 of Val and from NH-6 of Ile to C-1 of MeOzn1 were unambiguous. 
Additionally, a long range J coupling of 2.0 Hz was observed between the C(α)-H of the 
MeOzn1 and the C(α)-H of the Val residue. These long range J couplings are frequently found in 
cyclamides with oxazoline ring systems.11,14 From the HMBC spectrum recorded in CDCl3, 
correlations from NH-2 of Val to C-9 of MeOzn2 and from H-18 of Tzl to C-19 of Ile established 
the partial sequence -Tzl-Ile-MeOzn1-Val-MeOzn2- (Figure 1). The position of Ala was not 
directly established by the NMR data, but based on the molecular formula, balgacyclamide A (1) 
is required to be tetracyclic, therefore the peptide had to be macrocyclic. As a result, the sequence 
of the peptide was assigned as cyclo-(-MeOzn1-Val-MeOzn2-Ala-Tzl-Ile-)-. 
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Table 1. NMR Spectroscopic Data (500 MHz, DMSO-d6) for Balgacyclamide A (1). 
C/N no. δC, type δH (J in Hz) HMBC a 
1 168.9, C   
2 72.4, CH 4.41, dd (6.8, 2.0) 1, 4, 5 
3 79.3, CH 4.95, dq (6.5, 6.4) 1, 5 
4 20.4, CH3 1.37, d (6.4) 2, 3 
5 166.0, C   
6 50.6, CH 4.48, ddd (9.0, 2.5, 2.0) 5, 7, 8’ 
7 30.8, CH 1.98, m  
8 18.1, CH3 0.62, d (6.9) 6, 7, 8’ 
8’ 15.1, CH3 0.35, d (6.9) 6, 7, 8 
NH (2)  7.35, d (9.0) 5, 9 
9 169.7, C   
10 72.7, CH 4.33, d (6.7) 9 or 13, 11, 12 
11 81.1, CH 4.79, dq (6.7, 6.3) 9 or 13 
12 21.0, CH3 1.43, d (6.3) 9 or 13, 10, 11 
13 169.7, C   
14 42.6, CH 4.73, dq (7.7, 6.9) 13, 15, 16 
15 19.3, CH3 1.47, d (6.9) 14 
NH (4)  8.30, d (7.7)  
16 159.1, C   
17 148.0, C   
18 124.6, CH 8.30, s 17, 19 
19 169.7, C   
20 54.0, CH 5.23, dd (8.4, 5.7) 19, 21, 22 
21 40.4, CH 1.92, m  
 7 
22 14.2, CH3 0.93, d (6.8) 20, 21, 23 
23a 
23b 
25.1, CH2 1.44, m 
1.04, m 
 
21 
24 11.1, CH3 0.88, dd (7.4, 7.4) 21, 23 
NH (6)  8.21, d (8.4) 1 
a HMBC correlations are given from proton(s) stated to the indicated carbon atom. 
Balgacyclamide B (2) displayed an exact mass of m/z 551.2657, which supports the molecular 
formula C25H39N6O6S for the [M + H]+ pseudomolecular ion. Its molecular formula suggests that 
2 is an H2O adduct of balgacyclamide A (1). The constitution of 2 was obtained utilizing the 
same methods as for balgacyclamide A (1). As for 1, NH-Ala, NH-Val and NH-Ile were 
identified, but instead of two MeOzn in 1, one MeOzn and one NH-Thr were present accounting 
for the difference in the molecular formula. The sequence was established by HMBC long-range 
correlations (Figure 1). Correlations were observed from H-2 of MeOzn to C-5 of Val, from H-6 
of Val to C-9 of Thr, from H-10 of Thr to C-13 of Ala, from H-14 of Ala to C-16 of Tzl, from H-
18 of Tzl to C-19 of Ile and from H-20 of Ile to C-1 of MeOzn. As the 13C chemical shifts of the 
two carbonyls and of the thioimidate were close to each other (C-1 MeOzn ∂C 169.7, C-9 Thr ∂C 
169.4 and C-19 Ile ∂C 169.6), the sequence was confirmed by ROESY correlations. Correlations 
were observed between H-4 of MeOzn and H-6 of Val, between NH-2 of Val and H-10 and H-11 
of Thr, between NH-3 of Thr and H-14 and H-15 of Ala and between NH-6 of Ile and H-2 of 
MeOzn. As for cyclamide 1, a long range J coupling of 1.6 Hz was observed between the C(α)-H 
of MeOzn and the C(α)-H of the Val residue. Only the link between C-16 and C-17 of Tzl could 
not be established by the different NMR experiments. Again, according to the molecular formula, 
balgacyclamide B (2) was required to be tricyclic and therefore C-16 and C-17 needed to be 
connected, thus closing the macrocyclic ring of cyclo-(-MeOzn-Val-Thr-Ala-Tzl-Ile-)-. 
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Balgacyclamides A(1) and B(2) differ in only one structural variation, i.e. in the opening of the 
MeOzn residue to Thr. We think that this is not an artifact of the isolation procedure, as acidic 
conditions were avoided throughout the workup, and the presence of balgacyclamide B (2) was 
detected in the original extract. 
Table 2: NMR Spectroscopic Data (500 MHz, DMSO-d6) for Balgacyclamide B (2). 
C/H 
no. 
δC, type δH (J in Hz) HMBC a ROESY 
1 169.7, C    
2 73.4, CH 4.34, dd (6.2, 1.6) 1, 4, 5 4 
3 78.0, CH 4.84, dq (6.2, 6.2) 1, 2, 5  
4 20.0, CH3 1.29, d (6.2)  2, 3  
5 165.7, C    
6 51.1, CH 4.43, ddd (8.6, 3.7, 1.6) 5, 7, 8, 8’, 9 4, 8, 8’ 
7 30.3, CH 1.95, m 5, 6, 8, 8’ 8, 8’ 
8 17.8, CH3 0.67, d (6.9) 6, 7, 8’  
8’ 15.8, CH3 0.53, d (6.9) 6, 7, 8  
NH (2)  6.95, d (8.6) 5, 6, 9 6, 7, 8, 8’, 10, 11 
9 169.4, C    
10 58.5, CH 4.23, dd (8.7, 3.5) 9, 11, 13 12 
11 65.0, CH 4.19, m 12 12 
12 20.0, CH3 1.07, d (6.3) 10, 11  
OH  4.76, d (5.6) 10, 11, 12 12 
NH (3)  8.47, d (8.7) 10, 11, 13 10, 11, 12, 14, 15, 
OH, NH(2) 
13 172.4, C    
14 47.8, CH 4.80, m 13, 15, 16  
 9 
15 17.4, CH3 1.30, d (6.5) 13, 14  
NH (4)  8.22, d (7.9) 13, 14, 16 14, 15, NH(2) 
16 159.6, C    
17 147.9, C    
18 123.6, CH 8.22, s 17, 19  
19 169.6, C    
20 54.4, CH 5.13, dd (8.5, 5.5) 1, 19, 21, 22, 23 22, 23b 
21 39.5, CH 1.91, m 19, 20, 22, 23, 24 24 
22 14.1, CH3 0.90, d (6.8) 20, 21, 23  
23a 
23b 
25.2, CH2 1.44, m 
1.11, m 
20, 21, 22, 24 
20, 21, 22, 24 
 
24 10.9, CH3 0.88, dd (7.3, 7.3) 20, 21, 23  
NH (6)  8.43, d (8.5) 1, 20 2, 6, 20, 21, 23a, 24  
a HMBC correlations are given from proton(s) stated to the indicated carbon atom. 
Balgacyclamide C (3) displayed an exact mass of m/z 585.2512, which supports the molecular 
formula C28H37N6O6S for the [M + H]+ pseudomolecular ion. The six fragments MeOzn, NH-Phe, 
NH-Thr, NH-Gly, Tzl and NH-Ile were identified as described above. HMBC spectroscopy 
allowed the establishment of the sequence through a series of long-range correlations: from H-2 
of MeOzn to C-5 of Phe, from H-6 of Phe to C-12 of Thr, from NH-3 of Thr to C-16 of Gly, from 
H-17 of Gly to C-18 of Tzl, from H-20 of Tzl to C-21 of Ile and from NH-6 of Ile to C-1 of 
MeOzn, which established the sequence as cyclo-(-MeOzn-Phe-Thr-Gly-Tzl-Ile-)-. 
When comparing balgacycmide C (3) to its congeners, the replacement of a Val by a Phe 
residue and of the Ala by a Gly residue becomes apparent. Again, the Thr residue is present, 
which we attribute to the original metabolite (corroborated by its presence in the extract).  
Table 3: NMR Spectroscopic Data (500 MHz, DMSO-d6) for Balgacyclamide C (3). 
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C/H no. δC, type δH (J in Hz) HMBC a ROESY 
1 169.0, C    
2 73.8, CH 4.28, dd (7.6, 1.7) 1, 3, 4, 5  4 
3 78.3, CH 4.88, dq (7.6, 6.4) 1, 2, 5  
4 20.3, CH3 1.36, d (6.4) 2, 3  
5 165.0, C    
6 48.0, CH 4.76, m 5, 7, 8, 12 7a 
7a 
7b 
36.7, CH2 2.98, dd (13.6, 5.2) 
2.86, dd (13.6, 6.0) 
5, 6, 8, 9/9’ 
5, 6, 8, 9/9’ 
 
8 135.4, C    
9/9’ 129.0, CH 7.01, d (7.4) 7, 9/9’, 11 3, 6, 7b, OH 
10/10’ 127.4, CH 6.94, dd (7.4, 7.4) 8, 9/9’, 10/10’ 3, 6, 7b, OH 
11 126.0, CH 6.82, t (7.4) 9/9’  
NH (2)  7.45, d (7.5) 12 9/9’, 6, 13, 14 
12 169.2 C    
13 58.8, CH 4.19, dd (9.0, 4.5) 12, 14, 15 15 
14 65.4, CH 4.09, m 12 15 
15 19.8, CH3 0.92, d (6.3) 13, 14  
OH  4.91, d (5.4) 13, 14, 15 14, 15 
NH (3)  7.81, d (9.0) 13, 16 9/9’, 13, 14, 15, 17a, OH, 
NH(2) 
16 169.6, C    
17a 
17b 
42.9, CH2 4.39, dd (15.3, 7.5) 
3.63, dd (15.3, 3.3) 
16, 18 
16, 18 
 
NH (4)  8.26, dd (7.5, 3.3)  17a, 17b, NH(2), NH(3), 
NH(6) 
18 159.9, C    
19 147.5, C    
 11 
20 123.7, CH 8.29, s 18, 19, 21  
21 168.6, C    
22 54.1, CH 5.18, dd (8.1, 5.2) 21, 23, 24, 25 23, 26 
23 39.8, CH 1.92, m  26 
24 13.9, CH3 0.84, d (6.9) 22, 23, 25  
25a 
25b 
25.0, CH2 1.45, m 
0.98, m 
22, 23, 24, 26 
22, 23, 24 
 
26 11.2, CH3 0.87, dd (7.4, 7.4) 23, 25  
NH (6)  7.98, d (8.2) 1, 22 2, 22, 23, 24, 25a 
a HMBC correlations are given from proton(s) stated to the indicated carbon atom. 
 
 
Figure 1: Key COSY, ROESY and HMBC correlations in balgacyclamides A (1), B (2) and C 
(3). Note the observed long-range J coupling between H-2 and H-6 in both balgacyclamides A 
(1) and B (2). 
The configurations of balgacyclamides A-C (1-3) were determined by the same strategy as for 
the aerucyclamides.11 First, the compounds were ozonized to avoid the epimerization of the Ile 
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residues that are next to the thiazole residues, as it is known that amino acids next to thiazole or 
oxazole residues are prone to epimerization during hydrolysis.15 The compounds were then 
hydrolyzed, and half the amount of the hydrolyzed compounds was derivatized with the Marfey’s 
reagent16 while the other half was derivatized with trifluoroacetic acid anhydride. The Marfey’s 
derivatives were analyzed by HPLC-MS to establish the configurations of the Ala, Thr, Val and 
Phe amino acids by comparing the retention times with authentic derivatized amino acids as 
standards. Co-injection of authentic and natural samples was performed when necessary. The 
TFA derivatives were analyzed by GC-MS to establish the configuration of the Ile amino acids. It 
was necessary to perform a co-injection analysis with Ile standards to differentiate between the D-
Ile and D-allo-Ile residues. This methodology established the presence of D-Ala, L-Thr, L-Val and 
D-allo-Ile for balgacyclamides A and B (1 and 2) and L-Thr, L-Phe, D-allo-Ile for balgacyclamide 
C (3). These experiments therefore established the structures of balgacyclamides A-C (1–3). 
Balgacyclamides A (1) and B (2) were evaluated for their antiparasite activity. Compounds 1 
and 2 displayed micromolar IC50 activity (9.0 and 8.2 µM respectively) against the chloroquine-
resistant strain K1 of P. falciparum, whereas 1 and 2 showed only moderate activity against other 
parasites, IC50 = 59 and 51 µM respectively against Trypanosoma brucei rhodesiense STIB 900 
and IC50 = 28 µM for 2 against Leishmania donovani MHOM-ET-67/L82. Balgacyclamides A 
and B also displayed selectivity with respect to their cytotoxicity to the L6 rat myoblast cell line, 
for which no activity was detected up to 150 µM. These results are in agreement with previous 
antiparasite evaluations of cyclamide compounds. Venturamides A and B displayed IC50 values 
of 8.2 and 5.2 µM against P. falciparum,10 while aerucyclamides A, B, C and D displayed IC50 
values of 5.0, 0.7, 2.3 and 6.3 µM respectively.11 It is interesting to note that opening of the 
oxazoline ring in 1 did not result in significantly lower bioactivity. 
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Table 4. Biological Evaluation of Balgacyclamides A (1) and B (2) against Plasmodium 
falciparum K1, Trypanosoma brucei rhodesiense STIB 900, Trypanosoma cruzi Tulahuen C4, 
Leishmania donovani MHOM-ET-67/L82 and rat myoblast cells L6 (IC50 values are reported as 
µM concentrations). 
 P.f.a T. b. rhod.b T. cruzi c L. donovani d L6e 
1 9.0 59 >150 >150 >150 
2 8.2 51 >150 28 >150 
a Plasmodium falciparum K1 
b Trypanosoma brucei rhodesiense STIB 900 
c Trypanosoma cruzi Tulahuen C4 
d Leishmania donovani MHOM-ET-67/L82 
e Rat myoblast L6 cells 
 
In conclusion, we have reported the isolation and structure determination of balgacyclamides A 
(1), B (2) and C (3) from Microcystis aeruguinosa EAWAG 251. Balgacyclamides A (1) and B 
(2) were evaluated for their antiparasite activity and displayed micromolar IC50 activity against P. 
falciparum with good selectivity compared to their cytotoxicity. 
 
 
Experimental Section 
General Experimental Procedures. UV experiments were obtained with a Shimadzu UV-
1650PC double-beam spectrophotometer using a 1 cm path length cell. ECD spectra were 
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measured in MeOH with a ChirascanTM CD spectrometer in a 0.1 cm path length cell. NMR 
spectra were acquired on a Bruker Avance 500, a Bruker Avance III TCI 1.7 mm 
MicroCryoProbe, Bruker DRX-600 and Bruker Avance II 800 spectrometers, all equipped with 
cryoprobes. The spectra were referred to residual solvent proton and carbon signals (δH 2.50, δC 
39.5 for DMSO- d6 and δH 7.26, δC 77.2 for CDCl3). Accurate mass ESI spectra were recorded on 
a Micromass (ESI) Q-TOF Ultima API instrument. HPLC purification and analyses were 
performed on a Dionex HPLC system equipped with a P680 pump, an ASI-100 automated 
sample injector, a TCC-100 thermostated column compartment, a PDA-100 photodiode array 
detector, a Foxy Jr. fraction collector, and a MSQ-ESI mass spectrometric detector. The 
determination of the Ile enantiomers was carried out on a GC-FID instrument (Thermo Focus 
with a Thermo AS 3000 autosampler). 
Sources and Cultivation of Cyanobacteria. Microcystis aeruginosa EAWAG 251 was 
obtained from the Eawag (Swiss Federal Institute of Aquatic Science and Technology) Culture 
Collection of Cyanobacteria, currently at the University of Basel. This strain is identical as the M. 
aeruginosa PCC7820 from the Pasteur Culture Collection of Cyanobacteria, Paris, France. The 
strain was grown in a 20 L batch reactor (Zehnder medium17 ) with continuous aeration and a 
light/dark cycle of 12:12 h. The biomass was isolated by centrifugation and subsequently kept 
frozen until extraction. 
Extraction and Isolation. The biomass was extracted first with 100% MeOH and then twice 
with 60% MeOH. The extract was separated from the biomass by centrifugation. MeOH was 
removed from the combined extracts by evaporation under reduced pressure and the mixture was 
then dried by lyophilization. The resulting powder was dissolved in 80% MeOH and centrifuged 
to remove remaining particles. The solutions were then sequentially loaded to a C18 SPE column 
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(Supelco Discovery DSC-18, 10 g, conditioned with 10% aqueous MeOH), and eluted with 30%, 
60%, 80%, and 100% aqueous MeOH solutions. MeOH was removed from the combined 
fractions by evaporation under reduced pressure and the mixture was then dried by lyophilization. 
The resulting oil from the 80% MeOH fraction was redissolved in 80% MeOH, and the 
compounds were isolated using multiple C18 RP-HPLC runs (Phenomenex Gemini C18 5 μm; 150 
× 10 mm). The gradient MeOH/H2O at a flow of 5 mL/min was 35% MeOH to 100% over 30 
min. The column was then washed for 10 min with 100% MeOH and stabilized for the next cycle 
over 10 min with 35% MeOH. MeOH was removed under reduced pressure and the compounds 
were then dried with a stream of N2. Balgacyclamides A, B and C eluted at 17.4, 13.2 and 14.3 
min respectively. Balgacyclamide B and C were further purified by HPLC using multiple runs on 
an analytical column C18 RP-HPLC (Phenomenex Gemini C18 5 μm; 150 × 4.6 mm). The gradient 
CH3CN/H2O at a flow of 1 mL/min was 30% CH3CN to 100% over 60 min. The column was then 
washed for 10 min with 100% CH3CN and stabilized for the next cycle over 10 min with 30% 
CH3CN. Balgacyclamide B and C eluted at 10.0 and 11.2 min respectively. The compounds were 
dried as described above. The isolation yields of the balgacyclamides A (1), B (2) and C (3) were 
0.55 mg, 0.15 mg and 0.80 mg per 15 liters of culture, respectively. 
Balgacyclamide A (1): colorless, amorphous solid; UV (CH3CN) λmax (log ε) 224 nm (3.54); 
ECD (MeOH, c = 3.5 x 10-4) λmax (Δε) 244 (1.92), 207 (13.5); 1H and 13C NMR data (DMSO-d6), 
see Table 1; 1H and 13C NMR data (CDCl3), see supporting information; HRESI-QqTof-MS m/z 
533.2552 [M + H]+ (calcd for C25H37N6O5S, 533.2546). 
Balgacyclamide B (2): colorless, amorphous solid; UV (CH3CN) λmax (log ε) 237 nm (2.61); 
ECD (MeOH, c = 5.9 x 10-3) λmax (Δε) 231 (0.33), 209 (0.77); 1H and 13C NMR data (DMSO-d6), 
see Table 2; HRESI-QqTof-MS m/z 551.2657 [M + H]+ (calcd for C25H39N6O6S, 551.2652). 
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Balgacyclamide C (3): colorless, amorphous solid; UV (CH3CN) λmax (log ε) 242 nm (2.74); 
ECD (MeOH, c = 8.4 x 10-4) λmax (Δε) 248 (0.45); 1H and 13C NMR data (DMSO-d6), see Table 3; 
HRESI-QqTof-MS m/z 585.2512 [M + H]+ (calcd for C28H37N6O6S, 585.2495). 
Ozonolysis of Compounds 1–3: Each compound (0.1 mg, 0.2 μmol) was dissolved in 0.3 mL 
of dry CH2Cl2, ozonized at room temperature for 5 min and the solvent was removed under a 
stream of N2. 
Hydrolysis of Compounds 1–3: Each ozonized compound was hydrolyzed in a closed 
microwave tube by adding 0.5 mL of freshly prepared 6 N HCl at 108 °C for 20 h. The solvent 
was concentrated by a stream of N2 and removed by lyophilization and then the residue was 
dissolved in 0.06 mL of H2O. 
Marfey’s Analysis of Compounds 1–3: Half of the solution of the hydrolyzed compounds 
was treated with 0.03 mL of a 1% N-(2,4-dinitro-5-fluorophenyl)-L-alaninamide (FDAA) 
solution in acetone and 0.03 mL of 6% Et3N in H2O at 50°C for 1 h in a closed HPLC vial. The 
reaction was quenched with 0.03 mL of 5% acetic acid and the solvent was removed by 
lyophilisation. The residue was dissolved in 0.03 mL of MeOH and analyzed by RP-HPLC using 
an Agilent Zorbax SB-C18 column (3.55 μm 150 x 2.1 mm). The mobile phases were A, 5% 
acetic acid in H2O, and B, CH3CN/MeOH (9:1). The column was stabilized for 20 min with 5% 
of B, then the gradient went from 5-50% in 50 min and the column was washed with 100% of B 
for 20 min. The flow was set at 0.25 mL/min and the temperature of the column oven at 50 °C. 
By comparison of the retention times of the derivatized commercially available amino acids the 
configurations can be determined except for isoleucine. The retention times (min) for the 
derivatized standard amino acids were: L-Ala 28.25; D-Ala 32.21; L-Val 35.89; D-Val 40.64; L-
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Phe 41.01; D-Phe 46.39; L-Thr 21.09; L-allo-Thr 22.22; D-allo-Thr 24.73; D-Thr 28.89; L-Ile 
40.47; L-allo-Ile 40.45; D-Ile 47.38 and D-allo-Ile 47.46. 
TFA Derivatives and Chiral-Phase GC Analysis of 1, 2 and 3: 0.03 mL of the hydrolyzed 
compound solution was transferred to a GC vial and the solvent was evaporated. The residue was 
treated with 0.03 mL of trifluoroacetic acid anhydride at room temperature for 12 h and quenched 
with 0.03 mL of MeOH. The configuration of isoleucine was determined after analyses on a 
chiral-phase GC column (Permabond-L-Chirasil-Val; 25 m, 0.25 mm, Macherey-Nagel,) with the 
following conditions: 2 min at 80 °C, 80 to 180 °C at rate of 8 °C min-1 and 10 min at 180 °C 
with a split ratio 10:1, at a flow of 1 mL/min and an FID detector at 250 °C. 
The four commercially available stereoisomers of isoleucine were derivatized with the same 
method as presented above and the retention times (min) were: D-allo-Ile 6.20, L-allo-Ile 6.35, D-
Ile 6.39 and L-Ile 6.45. 
Configuration of Compounds 1–3: 
Balgacyclamide A (1): from ozonolysis−hydrolysis−Marfey D-Ala, L-Thr (confirmed by a co-
injection with L-allo-Thr), L-Val and D-Ile or D-allo-Ile and from ozonolysis−hydrolysis−TFA D-
allo-Ile (confirmed by a co-injection with D-Ile). 
Balgacyclamide B (2): from ozonolysis−hydrolysis−Marfey D-Ala, L-Thr, L-Val and D-Ile or 
D-allo-Ile and from ozonolysis−hydrolysis−TFA D-allo-Ile (confirmed by a co-injection with D-
Ile). 
Balgacyclamide C (3): from ozonolysis−hydrolysis−Marfey L-Thr, L-Phe and D-Ile or D-allo-
Ile and from ozonolysis−hydrolysis−TFA D-allo-Ile (confirmed by a co-injection with D-Ile). 
Biological Assays: 
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Plasmodium falciparum, Trypanosoma b. rhodesiense and in vitro cytotoxicity assays were 
performed according to procedures previously described.11b 
 19 
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